Nephros Inc(NEPH) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company is headquartered in South Orange, New Jersey and currently employs 7 full-time employees. In medical device markets, its filters are generally classified as ultrafilters, and are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. In commercial markets, the Company manufactures and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER brands. The Company’s product lines are: Water Filtration Products and Specialty Renal Products (HDF System). The Company’s subsidiary, Specialty Renal Products, Inc. (SRP), is a development-stage medical device company focused primarily on developing hemodiafiltration (HDF) technology.

Current Price

$7.97

RSI

50.345

Beta:

1.3458

December 31, 2020
1.1M
-1.5M

-23.917 %
-24.081 %
-105.691 %
-39.519 %

$8,842,000
$10,386,000
$5,303,000
$3,488,000
$2,152,000
$1,944,000
-14.866 %
95.851 %
52.036 %
62.082 %
10.700 %

$-4,692,000
$-3,645,000
$-3,495,000
$-2,598,000
$-4,015,483
$-3,088,000
-28.724 %
-4.292 %
-34.527 %
35.300 %
-30.035 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.